916991-31-6

Basic information

• Product Name: 5-(1-benzyl-piperidin-3-ylamino)-indazole-1-carboxylic acid tert-butyl ester
• Synonyms: 5-(1-benzyl-piperidin-3-ylamino)-indazole-1-carboxylic acid tert-butyl ester
• CAS NO: 916991-31-6
• Molecular Weight: 406.528
• Mol File: 916991-31-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5-(1-benzyl-piperidin-3-ylamino)-indazole-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(1-benzyl-piperidin-3-ylamino)-indazole-1-carboxylic acid tert-butyl ester(916991-31-6)
• EPA Substance Registry System: 5-(1-benzyl-piperidin-3-ylamino)-indazole-1-carboxylic acid tert-butyl ester(916991-31-6)

Safety Data

• Hazardous Substances Data: 916991-31-6(Hazardous Substances Data)

Upstream product

• 50606-58-1 N-benzyl-3-piperidinone hydrochloride 
• 129488-10-4 5-Amino-indazole-1-carboxylic acid tert-butyl ester 
• 129488-09-1 5-nitro-indazole-1-carboxylic acid tert-butyl ester 
• 5401-94-5 5-nitroindazole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 40114-49-6 1-benzyl-3-piperidone 

Downstream Products

• 1404375-45-6 C₂₆H₃₁N₅O₃S 
• 1404375-54-7 C₂₈H₂₉N₅O₃ 
• 1404375-56-9 C₂₈H₂₉N₅O₃ 
• 1404375-74-1 3-({3-[(1H-indazol-5-yl)amino]piperidin-1-yl}methyl)benzoic acid 
• 1404375-73-0 5-[1-(3-carboxy-benzyl)-piperidin-3-ylamino]-indazole-1-carboxylic acid tert-butyl ester 
• 1404375-76-3 5-[1-(3-carboxymethylbenzyl)-piperidin-3-ylamino]-indazole 
• 1404375-75-2 5-[1-(3-carboxymethyl-benzyl)-piperidin-3-ylamino]-indazole-1-carboxylic acid tert-butyl ester 
• 916989-51-0 5-[1-(4-acetylamino-phenyl)-piperidin-3-ylamino]-indazole-1-carboxylic acid tert-butyl ester 
• 1404375-21-8 C₂₄H₃₀N₄O₂ 

Relevant articles and documents

RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF

The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).

NOVEL ROCK INHIBITORS

The present invention relates to new kinase inhibitors of Formula (I), wherein X is oxygen, —NH—, or a direct bond; Y is —NH— or a direct bond; n is an integer from 0 to 4; m is an integer from 0 to 4; Cy represents a bivalent radical consisting of a satured (poly)cycle, including fused, bi-, spiro or bridged carbocycles and heterocycles; in particular selected from the group consisting of: Formula (II), Ar is selected from the group comprising: Formula (III), R2 is hydrogen or methyl; R8 is hydrogen, methyl, halogen, or alkynyl; R1 is an aryl or heteroaryl more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.

INDAZOLES

Methods and pharmaceutical compositions for treating and/or delaying the onset of viral infection are provided. The pharmaceutical compositions include compounds having an indazole core. Additionally, the compositions can be used to treat cardiovascular disorders and cancer.